Beurer GL 42 (mg/dL) - Manual (Page 8)

8 Beurer GL42 mg/dL
General notes
Warning
Do not use the device in the vicinity of strong electromagnetic fields and keep it away from radio
systems or mobile telephones.
Measuring the blood glucose content
Warning
• The measurements taken by you are for your information only – they are no substitute for a medical
examination! Consult your GP regularly regarding your measured values. Do not alter the procedures
prescribed by your GP.
• Despite the simple usage of the Beurer GL42 monitor for self-monitoring of blood glucose levels, you
may possibly need to obtain instructions for using the system from your healthcare professional (for
example, your GP, chemist or diabetes consultant). Only proper use will guarantee exact measure-
ments.
• A lack of water, high fluid loss, for example perspiration, frequent passing of water, severe hypoten-
sion (low blood pressure), shock or hyperosmolar hyperglycaemic non-ketotic coma may lead to
incorrect measured results.
• An excessively high or low hematocrit value (proportion of red blood cells) may lead to incorrect
measurements. In the event of a very high hematocrit value (above 60%), the displayed blood glu-
cose value may be too low; in the event of a very low hematocrit value (below 20%), it may be too
high. Consult your GP if you do not know your hematocrit value.
• Do not use the test strips to measure blood glucose values on newborns.
• Do not use NaF or potassium oxalate anticoagulants to prepare for venous blood samples.
• Do not test any severely ill patients using this device.
• The level of Acetaminophen (up to 10 mg/dL), Ascorbic acid (up to 4 mg/dL), Bilirubin (up to
20 mg/dL), Cholesterol (up to 500 mg/dL), Creatinine (up to 10 mg/dL), Dopamine (up to 5 mg/dL),
EDTA (up to 400 mg/dL), Fructose (up to 200 mg/dL), Galactose (up to 200 mg/dL), Gentistic acid
(up to 2 mg/dL), Glutathione (up to 3 mg/dL), Haemoglobin (up to 200 mg/dL), Heparin (up to
60 mg/dL), Ibuprofen (up to 40 mg/dL), Icodextrin (up to 200 mg/dL), Lactose (up to 200 mg/dL), L‐
DOPA (up to 3.0 mg/dL), Maltose (up to 200 mg/dL), Methyl‐DOPA (up to 1.25 mg/dL), Pralidoxime
Iodide (up to 1.25 mg/dL), salicylate (up to 20 mg/dL), Tetracycline (up to 4 mg/dL), Tolazamide
(up to 55 ug/dL), Tolbutamide (up to 100 mg/dL), Triglyceride (up to 3000 mg/dL), Uric acid (up to
7 mg/dL), and Xylose (up to 5 mg/dL) in blood has no significant interference reaction (the average
difference between the test sample and the control sample ≤ 0.55 mmol/L (10 mg/dL) at glucose
concentration of 50~100 mg/dL and ≤ 10% at glucose concentration of 250‐300 mg/dL) on GL42.
• The xylose level (up to 10 mg/dL) in the blood causes a significant deviation with the GL42 device
(average deviation between test and control test >0.55 mmol/L (10 mg/dL) with a blood glucose
concentration of 50-100 mg/dL and >10% with a blood glucose concentration of 250-300 mg/dL).
• Use fresh capillary whole blood only. Do not use serum or plasma.
• Use capillary blood without squeezing the penetration area. If the area is squeezed, the blood is di-
luted with tissue fluid and this may lead to an incorrect result.
• Do not use the test strips above an altitude of 6,000 m.